Humanized or chimeric CD3 antibodies

Patent metadata

Field	Value
Publication number	US-11359015-B2
Application number	US-201615744317-A
Country	US
Kind code	B2
Filing date	Jul 14, 2016
Priority date	Jul 15, 2015
Publication date	Jun 14, 2022
Grant date	Jun 14, 2022

Abstract

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

First claim

The invention claimed is:

1. A humanized or chimeric antibody which binds to human CD3, wherein said antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein:
a) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 176, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively;
b) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 184, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively; or
c) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 220, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively;
d) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 236, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively; or
e) the VH region comprises the CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 1, 2, and 244, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively.

2. The antibody according to claim 1 , wherein the antibody comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:s 1, 2, and 176, respectively, and a VL comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 6, the sequence GTN, and SEQ ID NO: 7, respectively.

3. The antibody according to claim 1 , wherein the antibody is a full-length antibody.

4. The antibody according to claim 1 , wherein the antibody is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

5. The antibody according to claim 1 , wherein the antibody is monovalent, bivalent or multivalent.

6. The antibody according to claim 1 , wherein said antibody comprises an Fc region comprising a first and a second immunoglobulin heavy chain.

7. The antibody according to claim 1 , wherein said antibody comprises a first and a second immunoglobulin heavy chain, wherein in at least one of said first and second immunoglobulin heavy chains one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

8. The antibody according to claim 7 , wherein in at least one of said first and second immunoglobulin heavy chains,
(a) the amino acid in the position corresponding to position D265 in a human IgG1 heavy chain is not D;
(b) the amino acid in the position corresponding to position N297 in a human IgG1 heavy chain is not N;
(c) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are not L and L, respectively;
(d) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E; or A and A, respectively;
(e) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E, respectively;
(f) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are A and A, respectively;
(g) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are not L, L, and D, respectively;
(h) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A; or A, A, and A, respectively;
(i) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A, respectively;
(j) the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain, are A, A, and A, respectively; or
(k) the amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain are F, E, A, Q, and S, respectively.

9. A composition comprising the antibody of claim 1 and a carrier.

10. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutical acceptable carrier.

11. A diagnostic composition comprising the antibody according to claim 1 .

12. A kit for detecting the presence of CD3 antigen, or a cell expressing CD3, in a sample comprising
i) the antibody according to claim 1 ; and
ii) instructions for use.

13. A humanized or chimeric antibody which binds to human CD3, wherein the antibody comprises:
a) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 177 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,
b) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 185 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,
c) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 221 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8,
d) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 237 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8, or
e) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 245 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8.

14. The antibody according to claim 13 , wherein the antibody comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 177 and a VL region comprising the amino acid sequence set forth in SEQ ID NO: 8.

15. The antibody according to claim 13 , wherein the antibody is a full-length antibody.

16. The antibody according to claim 13 , wherein the antibody is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

17. The antibody according to claim 13 , wherein the antibody is monovalent, bivalent or multivalent.

18. The antibody according to claim 13 , wherein said antibody comprises an Fc region comprising a first and a second immunoglobulin heavy chain.

19. The antibody according to claim 13 , wherein said antibody comprises a first and a second immunoglobulin heavy chain, wherein in at least one of said first and second immunoglobulin heavy chains the amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

20. The antibody according to claim 19 , wherein in at least one of said first and second immunoglobulin heavy chains,
(a) the amino acid in the position corresponding to position D265 in a human IgG1 heavy chain is not D;
(b) the amino acid in the position corresponding to position N297 in a human IgG1 heavy chain is not N;
(c) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are not L and L, respectively;
(d) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E; or A and A, respectively;
(e) the amino acids in the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E, respectively;
(f) the amino acids in the positions corresponding to positions L234 and L235 in a hu

Assignees

• Genmab As

Inventors

• Rademaker Rik
• Altintas Isil
• Engelberts Patrick
• Schuurman Janine
• Parren Paul

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title